Research

Dr. Shuibing Chen, an associate professor of chemical biology in surgery and in biochemistry at Weill Cornell Medicine, has received the ISSCR Dr. Susan Lim Award for Outstanding Young Investigator from the International Society for Stem Cell Research (ISSCR).

Treating early-stage lung cancers with drugs that unleash the immune system’s ability to attack malignant cells may hinder tumor growth and improve overall survival, according to new research by Weill Cornell Medicine and NewYork-Presbyterian investigators. 

Dr. Francis Lee, a leading physician-scientist whose research focuses on anxiety disorders, has been named chairman of the Department of Psychiatry at Weill Cornell Medicine and psychiatrist-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center, effective July 1.

Gene mutations detected in blood may predict risk of one of the most common forms of adult leukemia a decade before patients are diagnosed with the disease, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

An existing malaria drug could improve the effectiveness of a new class of cancer therapies, called glutaminase inhibitors, if used in combination, researchers at Weill Cornell Medicine-Qatar (WCM-Q) discovered in a new study.

A very low carbohydrate, high-fat diet called the ketogenic diet may improve the effectiveness of an emerging class of cancer drugs, according to a study in mice by investigators at Weill Cornell Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian.

Growing miniature tumors from patient’s cells in the laboratory may help scientists personalize treatments for those with a rare form of prostate cancer, according a study by Weill Cornell Medicine and NewYork-Presbyterian scientists.  

Dr. Li Gan, a neuroscientist internationally acclaimed for her research into neurodegenerative diseases, has been appointed director of the Helen and Robert Appel Alzheimer’s Disease Research Institute at Weill Cornell Medicine, effective July 1.

Dr. Dan Landau, an assistant professor of medicine and of physiology and biophysics at Weill Cornell Medicine, and a core faculty member of the New York Genome Center, has been awarded the Pershing Square Sohn Prize for Young Investigators in Cancer Research to support his work studying cancer evolution.

Many cases of early-stage kidney cancer can be treated with a relatively new, nonsurgical procedure used to destroy tumors, a new study by a team led by Weill Cornell Medicine and NewYork-Presbyterian suggests.

Dr. Anaïs Rameau is passionate about finding a way to restore these patients’ voices and, during Weill Cornell Medicine’s second annual Health Innovation Hackathon last month, challenged participants to do just that.

Patients who receive red blood cell (RBC) transfusions before, during or immediately after surgery are twice as likely to develop life-threatening, postoperative blood clots as those who don’t undergo RBC transfusions, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian researchers.

Dr. Fei Wang, an assistant professor of healthcare policy and research at Weill Cornell Medicine, received a...

Dr. Peter T. Meinke, an accomplished chemist with more than 30 years of industry and academic experience, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI).

Tiny carrier molecules called nanoparticles are often attached to radiation-emitting atoms in advanced medical imaging systems such as positron emission tomography (PET). These nanoparticles, paired with the right radioactive partners, can emit their own distinctive and readily detectable radiation—often visible light, according to a study from Weill Cornell Medicine scientists.

Dr. Samuel Bakhoum, a Holman research fellow at Weill Cornell Medicine and a senior resident in radiation oncology at Memorial Sloan Kettering Cancer Center, has won a 2018 Tri-Institutional Breakout Award for Junior Investigators.

Two thirds of children in the pediatric intensive care unit (PICU) who receive transfusions of platelets—a component of the blood that helps it to clot—do so to prevent bleeding, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian investigators. The other third of patients receive the transfusions to stop active bleeding.

A molecule promoting blood vessel growth in bone can create an environment suitable for bone-building formation, representing a potential target for new drugs to treat osteoporosis and fractures, according to new research by Weill Cornell Medicine scientists.

Dr. Tony Rosen, an assistant professor of medicine at Weill Cornell Medicine and an attending emergency physician at NewYork-Presbyterian/Weill Cornell Medical Center, has been named the recipient of this year’s Jeffrey H. Silverstein Memorial Award for Emerging Investigators in the Surgical and Related Medical Specialties.

Weill Cornell Medicine has established a new Mentoring Academy that is dedicated to nurturing the next generation of healthcare leaders.